Many neurological and psychiatric maladies originate from the deprivation of the human brain from estrogens. However, current hormone therapies cannot be used safely to treat these conditions commonly associated with menopause because of detrimental side effects in the periphery. The latter also prevents the use of the hormone for neuroprotection. We show that a small-molecule bioprecursor prodrug, 10b,17b-dihydroxyestra-1,4-dien-3-one (DHED), converts to 17b-estradiol in the brain after systemic administration but remains inert in the rest of the body. The localized and rapid formation of estrogen from the prodrug was revealed by a series of in vivo bioanalytical assays and through in vivo imaging in rodents. DHED treatment efficiently alleviated symptoms that originated from brain estrogen deficiency in animal models of surgical menopause and provided neuroprotection in a rat stroke model. Concomitantly, we determined that 17b-estradiol formed in the brain from DHED elicited changes in gene expression and neuronal morphology identical to those obtained after direct 17b-estradiol treatment. Together, complementary functional and mechanistic data show that our approach is highly relevant therapeutically, because administration of the prodrug selectively produces estrogen in the brain independently from the route of administration and treatment regimen. Therefore, peripheral responses associated with the use of systemic estrogens, such as stimulation of the uterus and estrogen-responsive tumor growth, were absent. Collectively, our brain-selective prodrug approach may safely provide estrogen neuroprotection and medicate neurological and psychiatric symptoms developing from estrogen deficiency, particularly those encountered after surgical menopause, without the adverse side effects of current hormone therapies.
INTRODUCTION
Estrogen deficiency in the human brain causes numerous neurological and psychiatric symptoms (1) . Hormone therapies, including systemically administered 17b-estradiol (E 2 , the main human estrogen), alleviate these conditions (2) . E 2 has also been shown to provide neuroprotection, as one of its best-documented nonreproductive functions, in animals (3). However, the full potential of the hormone for the treatment of estrogen-responsive central maladies cannot be realized in clinical settings until its actions are restricted to the brain. This is needed to ensure therapeutic safety, because adverse peripheral impact of estrogens has halted large-scale clinical trials investigating the long-term health benefits of hormone therapies based on equine estrogens (4) . Many women discontinued these therapies or avoid starting them, which potentially increases the risks of poor brain health even in conditions where benefits of estrogen have been shown (5, 6) . Therefore, novel therapies providing effective and safe treatment of the brain with estrogen remain an unmet need in medicine.
Elevated circulating estrogen levels and associated risks for harmful peripheral side effects are unavoidable with currently approved estrogen medications, even when human estrogen is prescribed (7) . The development of brain-selective estrogen therapies has been, however, a formidable challenge. Efforts to discover neuroselective estrogen receptor (ER) modulators are still focused mainly on a few well-known phytoestrogens (8) , and metabolism of these compounds is variable (9) . A recent development of a glucagon-like peptide-1 (GLP-1)-E 2 conjugate has shown potential brain delivery through dual-hormone action to improve energy, glucose, and lipid metabolism (10) . The approach targets cells that, besides ERs, also express GLP-1 receptors. Therefore, suprahypothalamic areas of the central nervous system (CNS) involved in many estrogen deficiency-derived neurological and psychiatric symptoms (6, 11) are not affected, because ER-expressing cells that coexpress GLP-1 receptors are localized only in the hypothalamus and the brainstem. An additional caveat of the method is due to key technical hurdles involved in the pharmaceutical development of effective peptide-based agents-including but not limited to manufacture, oral absorption, metabolic stability, pharmacokinetics, and formulation-compared with small-molecule drugs.
Hence, selective delivery of E 2 into the brain through a simple smallmolecule strategy would be of immediate practical relevance. Prodrug approaches to achieve this goal have, however, remained unsuccessful. Prodrugs are inactive derivatives of therapeutic agents that are converted to the biologically active parent drug by enzymatic and/or chemical transformations in vivo (12) . They are commonly developed to resolve pharmacokinetic, toxicity, formulation, and drug delivery limitations. A redox chemical delivery system, which applies the prodrug principle (12) , has been proposed for enhanced delivery of E 2 to the brain (13) . Although this method provides increased selectivity in CNS delivery of the hormone, it still generates elevated levels of the hormone in the periphery with substantial uterotrophic side effects and sustained high circulating estrogen levels even after acute dosing (14, 15) .
Our studies on the antioxidant mechanism of estrogen neuroprotection (16) inspired the hypothesis that 10b,17b-dihydroxyestra-1,4-dien-3-one (DHED) could serve as a bioprecursor prodrug of E 2 with preferential bioactivation to E 2 in the brain to fulfill the unmet need for brain-selective estrogen therapy. Unlike classical prodrugs, bioprecursor prodrugs do not contain auxiliary "promoieties" but are created via a transient chemical alteration within the drug molecule itself (12) . As an a,b-unsaturated carbonyl compound, DHED is a plausible substrate for a short-chain NADPH (reduced form of nicotinamide adenine dinucleotide phosphate)-dependent dehydrogenase/reductase (17) that is selectively expressed in the brain and linked to neuroprotection (18) . Using a series of bioanalytical and imaging assessments, evaluating gene expression, morphology, and neuropharmacological responses in several rodent models of neurological and psychiatric disorders, we show here that DHED selectively converts into E 2 only in the brain after systemic administration. We reveal the therapeutic potential of DHED on estrogen deficiency-associated neurological disorders and psychiatric conditions without encountering adverse systemic actions that are typically seen with the direct use of estrogens.
RESULTS

DHED conversion to estrogen (E 2 )
DHED is a bioprecursor prodrug that is converted to E 2 by a shortchain dehydrogenase/reductase (Fig. 1A) . The reductive bioactivation of DHED to E 2 proceeds through hydride transfer from the coenzyme NADPH to the C1 position of the C1-C2 double bond of DHED's Aring that is conjugated to the 3-carbonyl group. This b-addition is followed by spontaneous water elimination involving the 10(b)-OH. Our computer-aided mechanistic study fully supported this pathway of DHED's reductive bioactivation (Fig. 1B) . The first, enzyme-catalyzed hydride-transfer step leads to an intermediate through a transition state (which may be considered a resonance hybrid of the substrate-coenzyme and intermediate-oxidized coenzyme complexes shown in brackets) that is endergonic, with DG°of +2.1 kcal/mol. The subsequent water elimination is immensely exergonic (DG°of −10.3 kcal/mol); hence, it proceeds spontaneously, making the overall process also exergonic with DG°of −8.2 kcal/mol. The obtained phenolate form of E 2 (E 2 − ) is in acid-base equilibrium with the non-ionized (neutral) form of the hormone dictated by pH, and the neutral form predominates in equilibrium at physiological pH. Together, DHED's reductive bioactivation proceeds in an opposite direction compared to the well-known oxidative process converting an androgen to estrogen catalyzed by aromatase (19) . In the latter case, three sequential steps of substrate oxidation involving molecular oxygen and the transfer of six electrons are necessary for estrogen formation from androgens (Fig. 1C) . Table 1 summarizes key physicochemical, pharmacological, and biopharmaceutical properties of DHED in comparison with those of E 2 . DHED is inactive as an estrogen because it has no measurable affinity to the classical ERs and does not show the well-known antioxidant activity of the hormone (16) . Its lipophilicity and binding to human plasma proteins are significantly decreased, whereas its water solubility is increased compared with E 2 . All these are great advantages over E 2 in terms of bioavailability and formulation.
DHED metabolizes to E 2 only in the brain
In vitro metabolism studies were conducted by adding the prodrug to freshly prepared tissue homogenates. DHED was preferentially activated to E 2 in the brain compared with estrogen-sensitive peripheral tissues, such as the uterus ( Fig. 2A and fig. S1 ). Besides E 2 , we could not identify other steroid(s) formed from DHED. After intravenous dosing of ovariectomized (OVX) rats with DHED, appreciable level of circulating estrogens could not be detected and the prodrug disappeared rapidly from the circulation (Fig. 2B) . The distribution half-life (t d ) was estimated to be 5.1 ± 0.6 min. Concomitantly, E 2 concentrations increased in the brain. Experiments using deuterated d 3 -DHED demonstrated that d 3 -E 2 was produced exclusively in the brain (Fig. 2C) . Treatment with d 3 -DHED also did not trigger or inhibit endogenous E 2 formation in the brain, and did not S2 , C and D) administrations of the prodrug generated results similar to those obtained upon intravenous injection (Fig. 2B ). These findings revealed that the increase of E 2 in the brain after DHED treatment ( Fig. 2B and fig. S2 , A to C) originated from the conversion of the prodrug to E 2 -and not from the stimulation of endogenous hormone synthesis.
Results of detailed pharmacokinetic (PK) studies measuring E 2 concentrations in the brain and serum not only demonstrated a rapid uptake of DHED into the brain after systemic administration but also indicated its complete absorption after oral administration (table S1).
In vivo experiments using OVX repTOP ERE-Luc mice, in which luciferase expression is under the transcriptional control of ERs (20), also confirmed that prodrug treatments did not activate the ERE reporter construct and failed to generate bioluminescence in peripheral tissues accessible to in vivo imaging, even at high subcutaneous or oral doses (≥200 mg/kg) ( fig. S3A ). DHED was therefore not converted to E 2 in the periphery. In contrast, mice treated subcutaneously with E 2 at a dose of 20 mg/kg resulted in a significant increase of photon emission from the hepatic area ( fig. S3B ). Intracerebroventricular administration followed by ex vivo bioluminescence imaging of OVX repTOP ERE-Luc mice brain slices also revealed local estrogen formation from DHED ( fig. S3C ). The conversion occurred in all brain areas, with the cortical areas showing the highest extent of DHED bioactivation in this model, confirming our in vitro metabolism studies in OVX rat brain tissues ( Fig. 2A) .
DHED treatment is neuroprotective and elicits estrogen-responsive neuropharmacological effects in rodent models of CNS diseases We next evaluated the translational potential of DHED treatment in preclinical models of estrogen-responsive human CNS disorders, including stroke, depression, hot flushes, and cognitive decline (21) , in OVX rodents. Dose-dependent reduction of infarct volumes and attenuation of neurological deficits in animal models of stroke have been used frequently to quantify the extent of neuroprotection elicited by singledose estrogens (16, 22) . We used the most common paradigm, the transient middle cerebral artery occlusion (tMCAO) model followed by reperfusion, in our initial proof-of-concept studies. Neuroprotection was manifested by a dose-dependent reduction of the infarct volumes in DHED-treated animals ( Fig. 3A) , with concomitant attenuation of neurological deficits (Fig. 3B) . The effective subcutaneous dose (ED 50 , equivalent to 50% of the maximum effect) was about 15 mg/kg; nearly 10-fold higher systemic E 2 dose was needed to achieve the same protection against ischemic injury. These data indicate that the prodrug was significantly more potent to deliver E 2 into the brain than direct administration of the hormone. The ischemic brain retained its capacity to generate E 2 from the prodrug (Fig. 3C ) and, therefore, even postinfarct DHED treatment had a neuroprotective effect (Fig. 3, D and E) .
OVX rodents are highly responsive to estrogen, and the forced swim test (FST) using this model is widely used to screen for antidepressantlike activity (23) . When administered at identical doses, DHED treatments outperformed direct administration of E 2 in the FST (Fig. 4A) . The high-affinity ER antagonist ICI 182,780 completely blocked this antidepressant-like effect in both treatment groups (Fig. 4B) , suggesting an ER-mediated mechanism. In support, we detected a significant amount of ICI 182,780 in the brain (6.6 ± 0.9 ng/g tissue) by LC-MS/MS 15 min after completion of the FST. These data confirm the ability of this ER antagonist to enter the brain after systemic administration (24) .
We demonstrated similar efficacy of DHED treatment in additional animal models of menopause-associated neurological disorders. In a rat hot flush model (25) , oral DHED treatment blunted the tail-skin temperature rise (Fig. 4C ) using an orally bioavailable synthetic estrogen [17a-ethinylestradiol (EE)] as a positive control. In another animal model testing cognitive impairment owing to estrogen deficiency (26), we also measured the beneficial effect of DHED treatment. Continuous, long-term subcutaneous administration of DHED significantly decreased working memory errors committed by OVX middle-aged rats compared to control animals in a delay match-to-sample (DMS) plus maze test (Fig. 4D) .
DHED treatments produce markers of estrogenic effects in the brain To further validate that DHED delivery to the brain and its subsequent conversion to E 2 had functional and potentially therapeutic relevance, we assayed for clinically relevant markers of estrogenic effects on the brain (26) (27) (28) . DHED treatment stimulated progesterone receptor (PR) expression in the preoptic area of the hypothalamus (Fig. 5A) , increased choline acetyltransferase immunoreactive (ChAT-IR) stereological cell counts in the medial septum and vertical diagonal band (Fig. 5B) , and increased the number of dendritic spines and spine heads in hippocampal CA1 neurons (Fig. 5C ), all compared with vehicle control treatment. These changes in the brain were indistinguishable from those seen after direct subcutaneous estrogen treatment at the same concentration. ICI 182,780 abolished the effect of DHED treatment on PR induction (Fig. 5A) , which suggested that this response was indeed due to estrogen formed in situ from DHED.
DHED treatment does not have uterotrophic effects or promote proliferation of cancerous tissue
In addition to sparing the liver from estrogen exposure ( fig. S3, A and B) , DHED treatment did not result in wet uterus weight gain (Fig. 6A) , which is a uterotrophic effect of systemically administered estrogens (15, 29) . This was independent of the route of administration (intravenous, subcutaneous, or oral) ( fig. S4 ) and also did not occur after continuous, long-term (48-day) delivery of DHED using subcutaneous osmotic minipumps ( fig. S4C ). For these experiments, vaginal smears and standard cytology were used to confirm that all OVX animals were in diestrus before E 2 and DHED treatments were initiated. During and after DHED treatment, all animals in the DHED groups remained continuously in diestrus similar to those in the OVX control group, whereas all E 2 -treated rats exhibited vaginal smears with many cornified cells, indicating systemic estrogen exposure. In addition, although many protein markers are up-and down-regulated by exogenous E 2 (30) , there were no changes in the expression of a broad panel of estrogen-regulated uterine proteins compared with control after DHED treatment (Fig. 6B and fig. S5 ).
Another undesired consequence of increasing estrogen in the peripheral circulation is its effect on cancerous breast A) induced the expected cancer-promoting ERa transactivation in cultured human MCF-7Ca cells (31) , whereas DHED did not (Fig. 6C) . Unlike D 4 A, DHED treatment also did not stimulate the growth of aromatasetransfected MCF-7Ca breast cancer cells in vivo in a nude mouse xenograft model (Fig. 6D) , indicating that DHED indeed remained inert in these cells.
DISCUSSION
Estrogen-based therapies have remained the most effective remedies to treat menopausal indications; however, they are neither appropriate nor desirable for all symptomatic women. For example, estrogens are contraindicated after preventive oophorectomy (1, 32) , which is increasingly performed in gynecological oncology. Therefore, a growing population of women will not have effective and safe treatment against neurological and psychiatric maladies triggered by estrogen deficiency of the brain owing to surgical menopause (33). To address this major unmet medical need, we explored a new prodrug, DHED, that remains inert in the body-only to be quickly converted to estrogen in the brain. Evidence provided here indicates that the reductive bioactivation of DHED to estrogen is brain-selective in female animal models, which could offer unique benefits to the treatment of human diseases associated with brain estrogen deficiency or for those benefiting from estrogen-mediated neuroprotection.
Adverse consequences of estrogen deficiency in the human brain have been seen inevitably and most markedly upon bilateral oophorectomy performed before reproductive senescence, which precipitates premature menopause. Symptoms of premature menopause and also of menopause resulting from reproductive senescence include, among others, hot flushes, depression, cognitive impairment, and an increased risk of ischemic stroke (5, 6, 34) . Consequently, we chose widely accepted animal models of these human conditions to evaluate our DHED-based brain-selective intervention for a direct, side-by-side comparison with estrogen therapy. Collectively, our results indicate that DHED enters the brain of OVX rodents, where it is rapidly metabolized to the main estrogen, E 2 . In estrogen-sensitive peripheral tissues and in the circulation, DHED is not converted to E 2 and, thus, remains inert. Rapid metabolism of this prodrug to the hormone in the brain also explained why brain levels of DHED were undetectable. Overall, the significant elevation of brain E 2 levels after DHED treatments originated solely from the metabolism of the inactive bioprecursor and not from DHEDinduced E 2 biosynthesis.
In addition to abolishing affinity to ER and to other steroid receptors, the unique structural attributes (that is, a cyclohexadienone A-ring and the oxidatively added 10b-hydroxyl group) also favorably change key physicochemical and biopharmaceutical properties of DHED in comparison with those of E 2 . The benefits of these changes are shown in this study through rodent models demonstrating delivery of E 2 to the brain without toxic and uterotrophic systemic side effects seen for exogenous estrogen treatments. Compared to DHED treatment, an order of magnitude higher dose of estrogen was needed to generate a similar extent of neuroprotection and neuropharmacological responses in animal models of estrogen deficiency. This finding highlights brain-selective E 2 therapy by DHED as a better "drug economy"; that is, it focuses the biologically active estrogen to the brain-unlike systemic treatment with E 2 that distributes the hormone throughout the entire body.
DHED-based E 2 therapy was more efficacious than direct E 2 administration in a cerebrovascular stroke model. This improvement is attributed to the favorable physicochemical properties of DHED for blood-brain barrier transport from the circulation and based on mechanisms by which estrogens are known to protect neurons against ischemic injury. As expected from in vitro experiments indicating DHED bioactivation by the ischemic tissue, we also observed significant neuroprotection even when the animals received DHED up to 2 hours after the stroke. These additional results may expand the potential benefits of brain-selective estrogen therapy from stroke prevention in surgically menopausal women to effective post-stroke medication for all patients. E 2 has been shown to alleviate depression-like condition precipitated by a hypoestrogenic state in mice (23) , and the antidepressant activity of the hormone is due to a multimodal mechanism of action involving the regulation of several pathways and functions (11) . DHED treatment profoundly reduced behavioral immobility, which was reversible by an ER antagonist, the latter indicating that, similar to E 2 treatment, an estrogen was responsible for the observed pharmacological response. In our preclinical evaluation, DHED administration was also effective in an established rat model of hot flushes (25) , which are prevalent and long lasting during the menopause transition (35) .
A drop in E 2 levels after surgical menopause also may affect key parts of the brain responsible for memory and concentration, including the hippocampus, which has been shown to be associated with cognitive impairment (21, 36) . In young adult and middle-aged female rats, ovarian hormone loss induces cognitive impairment that can be reversed by systemic estrogen treatment (26) . In our study, middle-aged rats committed significantly fewer working memory errors in a DMS plus maze test after chronic administration of DHED than did the OVX control animals. The increase in brain E 2 after systemic DHED treatment appeared to have no direct effect on hippocampal estrogen biosynthesis. In subsequent experiments complementing the neuropharmacological assessments, we showed that E 2 generated from DHED in the brain produced the expression of characteristic markers indicating central estrogenic effects, and DHEDtreated groups were indistinguishable from the E 2 -treated control groups. In current clinical practice, chronic hormone therapies require the use of a progestin to counterbalance the detrimental impact of estrogens on the endometrium. Progestins, however, have been shown to interfere with the beneficial effect of estrogens in the brain (37) . Consistent with no change in circulating E 2 levels after DHED treatments, OVX rodents did not display E 2 -induced uterotrophic effects when dosed with DHED. All systemically estrogen-treated animals in our experiments showed the expected uterotrophic effect. The lack of uterine response upon DHED treatment was confirmed using proteomic markers of E 2 activity. Overall, uterine protein expression was not different between the DHED-and vehicle-treated groups. Thus, the lack of DHED's uterotrophic activity would obviate the need for coadministration of a progestin.
The induction of aromatase-dependent breast cancer has also been considered a serious risk of current estrogen therapies often contraindicating their use to manage symptoms of menopause clinically (33) . However, DHED-treated cells did not show ERa transactivation in vitro or stimulate MCF-7Ca xenografts in vivo. In further support of the inherent inertness and safety of DHED, we found that the liver A (100 mg/kg), or DHED (100 mg/kg) for 8 weeks. Data are averages ± SEM (n = 8 per treatment group). P values were determined by two-way ANOVA with treatment as the main factor and repeated measurements in time followed by SNK multiple comparison test.
was not exposed to estrogen after DHED treatment even at high oral doses (≥200 mg/kg). In contrast, subcutaneous administration of E 2 even at 1 / 10 th of DHED's dose showed the expected profound ER activation in the liver-a common hepatic side effect of current estrogen therapies.
Collectively, our comprehensive and multidisciplinary preclinical studies have revealed that E 2 's activity may be effectively confined to the brain of female rodents through the unique metabolism of a systemically administered bioprecursor prodrug. DHED has excellent oral bioavailability, which is a requirement along with additional drug-like properties, such as appropriate lipophilicity, reduced plasma-protein binding, and increased solubility in water, for successful pharmaceutical development. Our study indicates the translational potential of DHED for brain-selective estrogen therapy, especially to remedy neurological and psychiatric symptoms of early and surgical menopause, and potentially also in a wide range of human diseases associated with estrogen deficiency or benefiting from estrogen-mediated protection of the brain.
MATERIALS AND METHODS
Study design
This preclinical study was designed to test the ability of DHED to selectively metabolize to E 2 in the brain and thereby provide brainselective estrogen therapy. In vitro metabolism studies were performed using homogenates prepared from both healthy and diseased rat tissues. PK studies (with intravenous, subcutaneous, and oral dosing) measuring prodrug and estrogen concentrations, respectively, in target tissues and serum were carried out for proof of concept. Complementary in vivo imaging was done using various routes of prodrug administration (subcutaneous, oral, and intracerebroventricular). Confirmatory pharmacological assessments and assessment of markers revealing estrogenic effects were performed in animal models known to respond to exogenously administered E 2 . These paradigms enabled the direct comparison between the prodrug (DHED) and the parent drug (E 2 ) to highlight the distinguishing and unique properties of DHED in terms of brain-selective estrogen therapy (end points). For each experiment, sample sizes were chosen to minimize the number of OVX animals needed while obtaining sufficient statistical power. Treatment duration and dosage regimen were selected on the basis of published experiments involving estrogens after considering drug-like properties of DHED from in silico predictions and experimental measurements. Assays were carried out by blinded investigators.
Chemicals
The method used for the synthesis of DHED was based on a procedure adapted from the literature (38) using E 2 (Steraloids), m-chloroperbenzoic acid (Janssen Chimica) oxidant, and dibenzoyl peroxide (Aldrich) radical initiator in refluxing CH 2 Cl 2 under nitrogen for 3 hours while being irradiated with a 60-W tungsten lamp. Column chromatographic purification [silica gel; CH 2 Cl 2 /ethyl acetate, 7:3 (v/v)] and crystallization from toluene routinely afforded~45% yield [melting point: 215 to 217°C; DHED) according to a previously reported microwave-assisted procedure (39) . All other chemicals and reagents were purchased from commercial vendors.
Characterization of DHED Steroid receptor-binding experiments were performed by Caliper Life Sciences. Inhibition of lipid peroxidation was assayed in triplicate by the FTC and TBARS methods (40) . Binding to human plasma proteins was measured by rapid equilibrium dialysis (with a single-use dialysis plate with inserts, Thermo Scientific) according to the manufacturer's protocol. The logarithm of n-octanol/water partition coefficient (logP) was predicted by the method incorporated into the BioMedCAChe program (version 6.1, Fujitsu America Inc.) and was verified experimentally by the shake flask technique. Intrinsic water solubility (S w ) was measured in deionized water at 25°C and using an equilibrium solubility method adopted from an earlier procedure (41) by performing quantitative LC-MS/MS analyses (40) .
In vitro metabolic conversions of DHED to E 2 Initial in vitro conversion rates in freshly prepared 20% (w/v) OVX rat tissue homogenates were measured by the procedure and analytical method described previously (16) . Assays were performed in triplicate after addition of d 5 -E 2 from stock solution to reach internal standard concentration equivalent to 2 mM in the sample. Liquid-liquid extraction and quantitation by isotope dilution LC-MS/MS were done as reported before (40) .
Animal treatments and monitoring
Saline and corn or sesame oil vehicles were used for intravenous and subcutaneous injections, respectively, whereas compounds were delivered by gavage in a saline or phosphate-buffered saline (PBS) vehicle upon oral administration. PBS also served as a vehicle for intracerebroventricular injection. E 2 , EE, and DHED stock solutions were prepared in dimethyl sulfoxide (DMSO) or ethanol, which were admixed to the vehicles. Concentrations in the stock solutions and mixing ratios were chosen to keep the percentage of the organic co-solvent at a minimum while avoiding the precipitation of the compounds. For DHED, this represented ≤3% (v/v) of DMSO or ethanol in the administrationready solutions. For continuous subcutaneous administration by ALZET osmotic pumps (model 2ML4 rated for delivery at 0.25 ± 0.05 ml/hour for 28 days; Durect Corp.), E 2 or DHED was dissolved in propylene glycol. For control rats, pumps were filled only with propylene glycol. Pump insertion was done 18 days after ovariectomy under vaporized isoflurane anesthesia according to the surgical procedure recommended by the manufacturer. We replaced the pumps with freshly filled new ones after 15 days of delivery; this ensured that all animals had their assigned substrate delivered for the duration of behavioral testing and through euthanasia 48 days after the surgical insertion of the first pump. During the infusion period, we examined vaginal smears according to a previously reported procedure (42) . Transgenic Operative Products srl performed the experiments involving repTOP ERE-Luc mice, for which the animals were fed a special estrogen-free diet (43) .
Drug distribution in vivo
In vivo microdialysis experiments were performed as described previously (44) . Measurements from serum and brain tissue were made after dissecting the brain into regions, homogenization, liquid-liquid extraction, dansylation, and using 13 C-labeled internal standards ( 13 C 6 -E 2 and 13 C 6 -E 1 ; each at 100 pg/ml serum and 1.7 ng/g wet tissue) for quantification by isotope-dilution LC-MS/MS (45) . DHED analyses were carried out in separate LC-MS/MS assays using a Supelco Discovery HS C18 column, 50 mm × 2.1 mm, packed with 5-mm particles. The elution was isocratic at a flow rate of 0.25 ml/min with a mixture of acetonitrile and water [23: 77 (v/v)] containing 0.5% (v/v) acetic acid. DHED and the added internal reference compound (d 5 -DHED) in the effluent were detected by ion trap (LTQ) or triple-quadrupole (TSQ Quantum Ultra, Thermo Scientific) mass spectrometers equipped with ESI sources operated in the positive ionization mode. Quantifications were performed, similar to those of estrogens (45) , by isotope-dilution MS/MS. Protein contents in tissues were measured by a dye-binding assay (Thermo Scientific). Noncompartmental PK analyses (46) were performed by nonlinear curve fitting using Scientist for Windows (Micromath).
Focal ischemia/tMCAO-reperfusion injury model
Experiments were performed as previously described (47) , and the infarct volumes were measured after 1 hour of tMCAO followed by 24-hour reperfusion. Vehicle, E 2 , and DHED were injected subcutaneously 1 hour before tMCAO in the stroke prevention study, whereas DHED injections (100 mg/kg, subcutaneously) were also administered immediately upon starting reperfusion (that is, 1 hour after tMCAO), as well as 1 and 2 hours thereafter (2 and 3 hours after tMCAO, respectively). The harvested brains were kept in ice-cold saline for 5 min, after which seven coronal slices (2-mm thickness) were cut from each brain for 15-min incubation in 2% TCC solution at 37°C. Infarct volume was determined from measurements performed using the ImageJ software (U.S. National Institutes of Health). Neurological deficits were assessed and scored as follows: 0, normal (that is, no neurological deficit observed); 1, mild impairment (the animal failed to extend the contralateral forepaw on lifting the whole body by the tail); 2, moderate impairment (the animal circled contralaterally); 3, severe impairment (the animal leaned contralaterally when resting).
Computational study
All computations were performed with the SCIGRESS molecular modeling suit (version 2.6; Fujitsu-FQS Poland). Structures for ground and transition states were calculated using the PM6 and PM6-TS semiempirical quantum chemical parameterizations of the Molecular Orbital Package (MOPAC, Stewart Computational Chemistry) (48) . The conductor-like screening model (COSMO) was used to simulate continuum solvation in water (with the e permittivity parameter set to 78.4) (49). Thermodynamic quantities were calculated with the THERMO program of MOPAC.
Statistical analysis
We applied Shapiro-Wilk tests, visual inspections of histograms, normal Q-Q plots, and box plots to confirm normal distribution of data. Statistical evaluations were done by one-way ANOVA in all but one experiment (effect on MCF-7Ca breast cancer xenografts in athymic nude mice, where we used repeated-measures two-way ANOVA). All of our follow-up, two-group comparisons used SNK post hoc tests when a significant omnibus ANOVA (with two-tailed a set to 0.05) was found, noting that type I error correction was not necessary with orthogonal planned comparisons (50) . P < 0.05 was considered statistically significant.
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